Back to Clinical Trials
Phase 1Recruiting

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

Sponsored by Regeneron Pharmaceuticals

About this study

This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN). The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up. This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Where this study is enrolling

Who can participate

Inclusion criteria

  • ✓1. Diagnosis of Systemic Lupus Erythematosus (SLE) and LN, as described in the protocol
  • ✓2. Participant must have refractory or relapsed disease, as described in the protocol
  • ✓Key General

Exclusion criteria

  • ✕1. History of or active severe or unstable lupus-associated neuropsychiatric disease that is likely to require acute or emergent medical treatment or hospitalization
  • ✕2. Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within 12 months prior to screening or during screening
  • ✕3. Catastrophic or severe antiphospholipid syndrome within 12 months prior to screening or during screening
  • ✕NOTE: Other protocol defined inclusion/exclusion criteria apply

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.